logo

For the Inventor, By the Inventor

Hotaka, Japan

Junichi Kobayashi

This inventor holds 9 USPTO granted patents and 3 EPO patents. Top assignee: Kissei Pharmaceutical Co., Ltd.. Active years: 2008-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Junichi Kobayashi. Retrieved from https://idiyas.com/inventor/junichi-kobayashi-t7zfqujz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 9

% Patents Active = 11.1

 

Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Nagano, JP (2008)
  • Hotaka-machi, JP (2008 - 2010)
  • Azumino, JP (2016 - 2019)

Company Filing History:

goldMedal9 out of 176 
 
Kissei Pharmaceutical Co., Ltd.
 patents

Years Active: 2008-2019

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 10287251 - Pyrazole derivative or pharmaceutically acceptable salt thereof (2019-05-14),
2. 9458092 - α-Substituted glycinamide derivative (2016-10-04),
3. 7674938 - Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof (2010-03-09),
4. 7423185 - Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof (2008-09-09),
5. 7417169 - Amino alcohol derivatives, medicinal composition containing the same, and use of these (2008-08-26),
6. 7402692 - Intermediates in producing phenoxyacetic acid derivatives and method of using the same (2008-07-22),
7. 7396954 - Intermediates in producing phenoxyacetic acid preventives and method of using the same (2008-07-08),
8. 7393968 - Intermediates in producing phenoxyacetic acid derivatives and method of using the same (2008-07-01),
9. 7329771 - Intermediates in producing phenoxyacetic acid derivatives and method of using the same (2008-02-12),

Title: The Innovative Contributions of Junichi Kobayashi

Introduction

Junichi Kobayashi, a distinguished inventor based in Hotaka-machi, Japan, has made significant strides in the field of pharmaceutical innovations. With a total of nine patents to his name, Kobayashi's work focuses on developing novel compounds that have the potential to address critical medical challenges.

Latest Patents

Kobayashi's latest inventions include a pyrazole derivative, which serves as a pharmaceutical composition aimed at treating or preventing diseases linked to hyperexcitability or disorder of afferent neurons. This compound, represented by a specific formula, exhibits TRPM8 inhibitory effects, showcasing its potential therapeutic applications. Another crucial invention is the α-substituted glycinamide derivative, also designed to function as a pharmaceutical agent with similar inhibitory effects on TRPM8. This innovative compound promises to be beneficial in addressing various medical conditions associated with neuronal disorders.

Career Highlights

Junichi Kobayashi's affiliation with Kissei Pharmaceutical Co., Ltd. has been instrumental in his research and development efforts. His inventive spirit and robust portfolio of patents reflect a commitment to advancing pharmaceutical science and enhancing patient care.

Collaborations

Throughout his career, Kobayashi has collaborated with notable colleagues such as Takehiro Ishikawa and Tetsuro Tamai. These partnerships have enriched his research, fostering an environment of innovation and creativity in the quest for effective medical solutions.

Conclusion

Junichi Kobayashi stands out as a prominent figure in the realm of pharmaceutical inventions. His contributions, notably in developing compounds aimed at treating neuronal disorders, demonstrate the importance of innovation in addressing health challenges. With his ongoing dedication to research and collaboration, Kobayashi continues to play a vital role in the advancement of pharmaceutical sciences.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…